An update on dapagliflozin for chronic kidney disease.

IF 1.8 4区医学 Q2 Medicine

Drugs of today Pub Date : 2022-02-01 DOI:10.1358/dot.2022.58.2.3369188

Michael S Kelly

引用次数: 1

Abstract

Dapagliflozin is an oral agent for type 2 diabetes mellitus (T2DM) belonging to the sodium/glucose cotransporter 2 inhibitor (SGLT2-I) class of antihyperglycemic medications. In clinical trials, dapagliflozin has also been shown to reduce cardiovascular and major renal events. In the DAPA-CKD trial, dapagliflozin significantly reduced the composite renal outcome in patients with chronic kidney disease (CKD). Dapagliflozin represents a new pharmacologic option for reducing CKD progression in patients with and without diabetes.

查看原文本刊更多论文

达格列净治疗慢性肾病的最新进展

达格列净是治疗2型糖尿病(T2DM)的口服药物，属于钠/葡萄糖共转运蛋白2抑制剂(SGLT2-I)类降糖药物。在临床试验中，达格列净也被证明可以减少心血管和主要肾脏事件。在DAPA-CKD试验中，达格列净显著降低慢性肾脏疾病(CKD)患者的综合肾脏预后。达格列净代表了一种新的药理学选择，可减少有或无糖尿病患者的CKD进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drugs of today 医学-药学

CiteScore

3.90

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： An international, peer-reviewed journal publishing monographs on new products entering the market and review articles. Since its inception in 1965, Drugs of Today has established a reputation for excellence in providing physicians and other key healthcare professionals with practical, up-to-date monographs on recently approved and launched drugs.